Loading…
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-71M | $-66M | $-49M | -33.8% | -100.0% | - |
| 2024 | $1M | $-55M | $-49M | $-45M | -39.4% | - | - |
| 2023 | $0M | $-48M | $-42M | $-41M | -28.6% | - | - |
| 2022 | $0M | $-40M | $-39M | $-34M | -21.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0.85 | 0 |
| Operating Expense | 41.66 | 50.36 | 57.48 | 72.84 |
| Operating Income | -41.66 | -50.36 | -56.62 | -72.84 |
| EBITDA | -39.75 | -48.47 | -54.87 | -71.37 |
| EBIT | -41.66 | -50.36 | -56.62 | -72.84 |
| Pretax Income | -39.23 | -42.49 | -49.38 | -66.49 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -39.23 | -42.49 | -49.38 | -66.49 |
| Net Income Common Stockholders | -39.23 | -42.49 | -49.38 | -66.49 |
| Total Expenses | 41.66 | 50.36 | 57.48 | 72.84 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 2.36 | 7.90 | 7.30 | 6.40 |
| Research And Development | 30 | 38.12 | 42.34 | 55.97 |
| Selling General And Administration | 11.66 | 12.24 | 15.13 | 16.87 |
| Normalized EBITDA | -39.82 | -48.47 | -54.87 | -71.37 |
| Normalized Income | -39.30 | -42.49 | -49.38 | -66.49 |
| Basic EPS | -0.37 | -0.33 | -0.36 | 0 |
| Diluted EPS | -0.37 | -0.33 | -0.36 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.07 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0.07 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -39.23 | -42.49 | -49.38 | -66.49 |
| Reconciled Depreciation | 1.90 | 1.89 | 1.75 | 1.47 |
| Net Interest Income | 2.36 | 7.90 | 7.30 | 6.40 |
| Net Income From Continuing And Discontinued Operation | -39.23 | -42.49 | -49.38 | -66.49 |
| Total Operating Income As Reported | -41.66 | -50.36 | -56.62 | -72.84 |
| Diluted Average Shares | 105.19 | 127.03 | 137.15 | 0 |
| Basic Average Shares | 105.19 | 127.03 | 137.15 | 0 |
| Diluted NI Availto Com Stockholders | -39.23 | -42.49 | -49.38 | -66.49 |
| Net Income Including Noncontrolling Interests | -39.23 | -42.49 | -49.38 | -66.49 |
| Net Income Continuous Operations | -39.23 | -42.49 | -49.38 | -66.49 |
| Other Income Expense | 0.07 | -0.03 | -0.05 | -0.05 |
| Other Non Operating Income Expenses | 0 | -0.03 | -0.05 | -0.05 |
| Special Income Charges | 0.07 | 0 | 0 | 0 |
| Gain On Sale Of Ppe | 0.07 | 0 | 0 | 0 |
| Other Special Charges | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 2.36 | 7.90 | 7.30 | 6.40 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 2.36 | 7.90 | 7.30 | 6.40 |
| General And Administrative Expense | 11.66 | 12.24 | 15.13 | 16.87 |
| Other Gand A | 11.66 | 12.24 | 15.13 | 16.87 |
| Operating Revenue | 0 | 0 | 0.85 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc.this co. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Greenwich LifeSciences, Inc. | GLSI | $299M | - | 136.71 | -623.1% | -15.09 |
| Rezolute, Inc. | RZLT | $299M |
| - |
| 2.53 |
| -45.9% |
| -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| Peer Median | - | 15.33 | 2.25 | -47.4% | -1.89 | |